Does the media prefer ALLO or CRSP?

In the previous week, CRISPR Therapeutics had 11 more articles in the media than Allogene Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.22 beat CRISPR Therapeutics' score of 0.74 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or CRSP?

In the previous week, CRISPR Therapeutics had 5 more articles in the media than Axsome Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 8 mentions for Axsome Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.74 beat Axsome Therapeutics' score of 0.23 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BEAM or CRSP?

In the previous week, CRISPR Therapeutics had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 10 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.74 beat Beam Therapeutics' score of 0.67 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or EDIT?

In the previous week, CRISPR Therapeutics had 10 more articles in the media than Editas Medicine. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 3 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.74 beat Editas Medicine's score of 0.44 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend KALA or CRSP?

CRISPR Therapeutics has a consensus price target of $67.94, indicating a potential upside of 22.81%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than KALA BIO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.67

Does the media refer more to KALA or CRSP?

In the previous week, CRISPR Therapeutics had 7 more articles in the media than KALA BIO. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 6 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 0.74 beat KALA BIO's score of 0.40 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

CRISPR Therapeutics (CRSP) Competitors

$55.32 -0.68 (-1.21%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$55.33 +0.01 (+0.02%)

As of 09/30/2026 07:57 PM Eastern

Compare

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

Should you buy CRISPR Therapeutics stock or one of its competitors? CRISPR Therapeutics's main competitors and comparable companies include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and KALA BIO (KALA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Allogene Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

Allogene Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	27,639.20	-$190.89M	-$0.67	N/A
CRISPR Therapeutics	$3.51M	1,523.90	-$581.60M	-$4.76	N/A

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Allogene Therapeutics currently has a consensus target price of $8.30, indicating a potential upside of 418.75%. CRISPR Therapeutics has a consensus target price of $67.94, indicating a potential upside of 22.81%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 11 more articles in the media than Allogene Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.22 beat CRISPR Therapeutics' score of 0.74 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Axsome Therapeutics presently has a consensus price target of $275.84, suggesting a potential upside of 49.60%. CRISPR Therapeutics has a consensus price target of $67.94, suggesting a potential upside of 22.81%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Axsome Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

Axsome Therapeutics has a net margin of -24.68% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

In the previous week, CRISPR Therapeutics had 5 more articles in the media than Axsome Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 8 mentions for Axsome Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.74 beat Axsome Therapeutics' score of 0.23 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Axsome Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	15.13	-$183.17M	-$3.75	N/A
CRISPR Therapeutics	$3.51M	1,523.90	-$581.60M	-$4.76	N/A

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Axsome Therapeutics beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Beam Therapeutics has a net margin of -54.75% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Beam Therapeutics currently has a consensus price target of $49.00, suggesting a potential upside of 100.41%. CRISPR Therapeutics has a consensus price target of $67.94, suggesting a potential upside of 22.81%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

Beam Therapeutics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 10 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.74 beat Beam Therapeutics' score of 0.67 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	18.07	-$79.99M	-$0.86	N/A
CRISPR Therapeutics	$3.51M	1,523.90	-$581.60M	-$4.76	N/A

Summary

Beam Therapeutics beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Editas Medicine?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Editas Medicine has a net margin of -157.32% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Editas Medicine	-157.32%	-196.63%	-38.17%

CRISPR Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 10 more articles in the media than Editas Medicine. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 3 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.74 beat Editas Medicine's score of 0.44 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,523.90	-$581.60M	-$4.76	N/A
Editas Medicine	$40.52M	9.74	-$160.06M	-$0.75	N/A

CRISPR Therapeutics presently has a consensus price target of $67.94, indicating a potential upside of 22.81%. Editas Medicine has a consensus price target of $5.80, indicating a potential upside of 125.68%. Given Editas Medicine's higher possible upside, analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

CRISPR Therapeutics and Editas Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

KALA BIO has a beta of -2.28, meaning that its share price is 328% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CRISPR Therapeutics has a consensus price target of $67.94, indicating a potential upside of 22.81%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than KALA BIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-222.35%	-70.23%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

In the previous week, CRISPR Therapeutics had 7 more articles in the media than KALA BIO. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 6 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 0.74 beat KALA BIO's score of 0.40 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KALA BIO	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

KALA BIO has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A
CRISPR Therapeutics	$3.51M	1,523.90	-$581.60M	-$4.76	N/A

Summary

CRISPR Therapeutics beats KALA BIO on 13 of the 16 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRSP vs. The Competition

Export

Metric	CRISPR Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.41B	$3.96B	$7.30B	$13.05B
Dividend Yield	N/A	3.63%	2.52%	14.40%
P/E Ratio	-11.62	13.36	273.69	25.69
Price / Sales	1,523.90	1,312.63	662.10	111.80
Price / Cash	N/A	120.99	79.75	52.21
Price / Book	2.74	15.13	10.34	6.29
Net Income	-$581.60M	-$22.71M	$3.50B	$360.55M
7 Day Performance	-0.68%	-1.49%	-1.34%	-1.54%
1 Month Performance	-2.64%	-7.57%	-4.64%	-3.09%
1 Year Performance	-16.38%	24.70%	11.06%	2.89%

CRISPR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRSP CRISPR Therapeutics	2.6057 of 5 stars	$55.32 -1.2%	$67.94 +22.8%	-14.6%	$5.41B	$3.51M	N/A	393	Analyst Forecast
ALLO Allogene Therapeutics	2.4462 of 5 stars	$1.63 -1.2%	$8.30 +409.2%	+29.0%	$563.15M	$20K	N/A	152	Positive News
AXSM Axsome Therapeutics	3.254 of 5 stars	$193.89 -0.6%	$271.65 +40.1%	+51.8%	$10.16B	$638.50M	N/A	925	Analyst Forecast
BEAM Beam Therapeutics	2.4126 of 5 stars	$24.23 -0.2%	$49.00 +102.2%	+0.7%	$2.50B	$139.74M	N/A	540
EDIT Editas Medicine	2.1126 of 5 stars	$2.51 -2.7%	$5.80 +131.1%	-25.9%	$385.49M	$40.52M	N/A	87

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRSP) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Which has more volatility & risk, ALLO or CRSP?

Which has better earnings & valuation, ALLO or CRSP?

Is ALLO or CRSP more profitable?

Do analysts prefer ALLO or CRSP?

Do insiders & institutionals have more ownership in ALLO or CRSP?

Does the media prefer ALLO or CRSP?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Do analysts recommend AXSM or CRSP?

Is AXSM or CRSP more profitable?

Does the media prefer AXSM or CRSP?

Which has more volatility & risk, AXSM or CRSP?

Which has better valuation & earnings, AXSM or CRSP?

Do institutionals & insiders hold more shares of AXSM or CRSP?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Is BEAM or CRSP more profitable?

Do analysts prefer BEAM or CRSP?

Which has more risk & volatility, BEAM or CRSP?

Does the media prefer BEAM or CRSP?

Do institutionals & insiders hold more shares of BEAM or CRSP?

Which has better earnings and valuation, BEAM or CRSP?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Do institutionals & insiders have more ownership in CRSP or EDIT?

Is CRSP or EDIT more profitable?

Which has more volatility and risk, CRSP or EDIT?

Does the media favor CRSP or EDIT?

Which has stronger valuation and earnings, CRSP or EDIT?

Do analysts rate CRSP or EDIT?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Which has more volatility & risk, KALA or CRSP?

Do insiders and institutionals have more ownership in KALA or CRSP?

Do analysts recommend KALA or CRSP?

Is KALA or CRSP more profitable?

Does the media refer more to KALA or CRSP?

Which has stronger valuation and earnings, KALA or CRSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools